Open letter to AbbVie on access to critical hepatitis C treatment – glecaprevir/pibrentasvir (G/P)
Médecins Sans Frontières (MSF) Access Campaign wrote an open letter to pharmaceutical corporation AbbVie to express our urgent need for glecaprevir/pibrentasvir (G/P) combination to treat people with hepatitis C.
Over a period of more than one year, MSF has made numerous requests for AbbVie to allow us to procure G/P for people living with hepatitis C in our care. These requests have gone unanswered. We do not know how much G/P costs and have not been allowed to buy it.
In our letter, we urge AbbVie to:
- Allow MSF to immediately procure G/P for our patients in need;
- Expedite registration of G/P in low- and middle-income countries and make prices transparent and publicly available; and
- Expand the territory of its voluntary licensing agreement with the Medicines Patent Pool to ensure generics companies have sufficient incentive to develop and supply this important hepatitis C treatment.
